Therapeutic drug monitoring of posaconazole oral suspension in paediatric hematology patients under 13 years of age.

ABSTRACT:

Background

Posaconazole oral suspension is not approved for use in children younger than 13 years of age, and the optimal dosing regimen is unclear. The target trough concentration of posaconazole for the effective prevention of invasive fungal infections in adults is influenced by multiple factors, but reports in children aged <13 years remain limited. Therefore, the primary objective of this study was to evaluate potential risk factors affecting the steady-state trough concentration of oral posaconazole suspension in a large population of Chinese children.

Methods

This observational, single-center study retrospectively analyzed pediatric patients younger than 13 years of age who received posaconazole oral suspension for the prevention of invasive fungal disease and impleme

SUBMITTER: Du X 

PROVIDER: S-EPMC11811588 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature